| Outcome Measures: |
Primary: 24-hr glucose (Calculated plasma glucose AUC0-24, change in fasting plasma glucose), Repeated sampling during the 24 hour period on day -1, 4 and 8 | Secondary: Safety and tolerability (Adverse events (AEs) during the study, blood pressure (BP), pulse rate, safety laboratory variables (incl. glucose) and investigator's interpretation of electrocardiogram (ECG), Frequent measurements during the study period|Pharmacokinetic variables (Area under the plasma conc vs. time curve (AUC0-24), maximum plasma conc (Cmax), time to reach maximum plasma conc(tmax), terminal elimination half-life and apparent oral clearance, Repeated sampling at pre-specified timepoints on day 4 and 8|Pharmacodynamics (S-Insulin AUC0-24 and C-peptide AUC0-24), Repeated sampling during the 24 hour period on day -1, 4 and 8
|
